Search Results

You are looking at 141 - 150 of 530 items for :

  • "Adjuvant therapy" x
  • Refine by Access: All x
Clear All
Full access

Differences in Medicare Expenditures Between Appalachian and Nationally Representative Cohorts of Elderly Women With Breast Cancer: An Application of Decomposition Technique

Ami Vyas, S. Suresh Madhavan, and Usha Sambamoorthi

months) after BC diagnosis constituted 37% of BC Medicare spending, which is substantially higher due to surgery and adjuvant therapy. 2 – 6 Additionally, elderly women aged ≥65 years have higher BC incidence compared with their younger counterparts, 7

Full access

Multidisciplinary Management of Locally Advanced Rectal Cancer: Neoadjuvant Approaches

Swaminathan Murugappan, William P. Harris, Christopher G. Willett, and Edward Lin

different benefits were seen from adjuvant therapy. 64 Patients were followed for a median of 4 years, with 41% of patients administered fluoropyrimidine-based adjuvant therapy. Patients with intermediate tumor response benefited the most from adjuvant

Full access

Challenges in the Management of Older Patients With Colon Cancer

Efrat Dotan, Ilene Browner, Arti Hurria, and Crystal Denlinger

was sufficient to warrant consideration of adjuvant chemotherapy. Because cancer was found to be the primary cause of death in this population, adjuvant therapy is likely to improve disease outcomes. The lower rates of adjuvant therapy use among

Full access

Abstracts From the NCCN 2019 Annual Conference: Improving the Quality, Effectiveness, and Efficiency of Cancer CareTM

03689712) is in progress. Clinical trials to reduce RT-related esophagitis are also planned. CLO19-040: The Role of Adjuvant Therapy in Patients With Pathological T2N0 Resected Gastric Adenocarcinoma John Khoury, MD a ; David Macari, MD a ; Daniel Ezekwudo

Full access

Breast Cancer Version 3.2014

William J. Gradishar, Benjamin O. Anderson, Sarah L. Blair, Harold J. Burstein, Amy Cyr, Anthony D. Elias, William B. Farrar, Andres Forero, Sharon Hermes Giordano, Lori J. Goldstein, Daniel F. Hayes, Clifford A. Hudis, Steven J. Isakoff, Britt-Marie E. Ljung, P. Kelly Marcom, Ingrid A. Mayer, Beryl McCormick, Robert S. Miller, Mark Pegram, Lori J. Pierce, Elizabeth C. Reed, Kilian E. Salerno, Lee S. Schwartzberg, Mary Lou Smith, Hatem Soliman, George Somlo, John H. Ward, Antonio C. Wolff, Richard Zellars, Dorothy A. Shead, and Rashmi Kumar

experienced breast surgery team that works in a coordinated, multidisciplinary fashion to guide proper patient selection for skin-sparing mastectomy, determine optimal sequencing of the reconstructive procedures in relation to adjuvant therapies, and perform a

Full access

Rectal Cancer, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology

Al B. Benson III, Alan P. Venook, Mahmoud M. Al-Hawary, Lynette Cederquist, Yi-Jen Chen, Kristen K. Ciombor, Stacey Cohen, Harry S. Cooper, Dustin Deming, Paul F. Engstrom, Jean L. Grem, Axel Grothey, Howard S. Hochster, Sarah Hoffe, Steven Hunt, Ahmed Kamel, Natalie Kirilcuk, Smitha Krishnamurthi, Wells A. Messersmith, Jeffrey Meyerhardt, Mary F. Mulcahy, James D. Murphy, Steven Nurkin, Leonard Saltz, Sunil Sharma, David Shibata, John M. Skibber, Constantinos T. Sofocleous, Elena M. Stoffel, Eden Stotsky-Himelfarb, Christopher G. Willett, Evan Wuthrick, Kristina M. Gregory, Lisa Gurski, and Deborah A. Freedman-Cass

. Preoperative chemoRT may result in tumor downsizing and a decrease in tumor bulk (see “Neoadjuvant and Adjuvant Therapy for Resectable Nonmetastatic Disease,” page 885); sphincter preservation may become possible in cases where initial tumor bulk prevented

Full access

A Publicly Funded Clinical Trials Network: Do We Need It?

Margaret Tempero

landmark studies, such as those that defined adjuvant therapy in breast and colorectal cancers, two of the biggest success stories. So my answer to the title question is “yes,” we need a publicly funded clinical trials network. The pharmaceutical industry

Full access

Factors Associated With Delays in Chemotherapy Initiation Among Patients With Breast Cancer at a Comprehensive Cancer Center

Katya Losk, Ines Vaz-Luis, Kristen Camuso, Rafael Batista, Max Lloyd, Mustafa Tukenmez, Mehra Golshan, Nancy U. Lin, and Craig A. Bunnell

In an era of increasing use of Oncotype DX to assist with chemotherapy treatment decisions, an aging population with comorbidities needing to be addressed, and the more prevalent use of MIR, it is not surprising that wait times to adjuvant therapy

Full access

Vulvar Cancer, Version 1.2017, NCCN Clinical Practice Guidelines in Oncology

Wui-Jin Koh, Benjamin E. Greer, Nadeem R. Abu-Rustum, Susana M. Campos, Kathleen R. Cho, Hye Sook Chon, Christina Chu, David Cohn, Marta Ann Crispens, Don S. Dizon, Oliver Dorigo, Patricia J. Eifel, Christine M. Fisher, Peter Frederick, David K. Gaffney, Ernest Han, Susan Higgins, Warner K. Huh, John R. Lurain III, Andrea Mariani, David Mutch, Christa Nagel, Larissa Nekhlyudov, Amanda Nickles Fader, Steven W. Remmenga, R. Kevin Reynolds, Todd Tillmanns, Stefanie Ueda, Fidel A. Valea, Emily Wyse, Catheryn M. Yashar, Nicole McMillian, and Jillian Scavone

has shifted from radical approaches to more conservative surgery with the addition of RT or chemoradiation. 15 Because the data are limited, trials are ongoing to identify optimal approaches for neoadjuvant and adjuvant therapy, which may include

Full access

Pre-Judging Data: Benchmarking Clinical Significance Before Study Results Are Known

Harold J. Burstein

, hopefully unbiased, fashion. Let’s apply this strategy to two important trials in early-stage breast cancer; the HERA study, which compared 0 versus 1 versus 2 years of trastuzumab as adjuvant therapy for HER2-positive breast cancers (the comparison of 1